{"page":{"totalFilteredElements":330},"studies":[{"active":true,"description":"
A Phase III, Randomized, Double-blind, Multicenter, Global Study of Rilvegostomig or Pembrolizumab in Combination with Platinum-based Chemotherapy for the First-line Treatment of Patients with Metastatic Non-squamous Non-small Cell Lung Cancer Whose Tumors Express PD-L1 (ARTEMIDE-Lung03; D702FC00001)
","eudractNumber":"2024-515008-38-00","id":11262,"indications":[{"id":"lun","name":"Lungentumoren"},{"id":"lun2","name":"Nicht-kleinzelliges Bronchialkarzinom (NSCLC)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[{"name":"PD-1 (Programmed cell death protein 1)","id":"mt_43"},{"name":"PD-L1","id":"mt_25"}],"nctNumber":"NCT06627647","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2025-07-08T12:51:32+02:00","shortTitle":"ARTEMIDE-Lung03","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]},{"active":true,"description":"A\nPhase III, Randomized, Double-blind, Multicenter, Global Study of Rilvegostomig\nor Pembrolizumab Monotherapy for the First-line Treatment of Patients with\nPD-L1-high Metastatic Non-small Cell Lung Cancer (ARTEMIDE-Lung04)","eudractNumber":"2024-517780-24-00","id":10715,"indications":[{"id":"lun","name":"Lungentumoren"},{"id":"lun2","name":"Nicht-kleinzelliges Bronchialkarzinom (NSCLC)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[{"name":"PD-1 (Programmed cell death protein 1)","id":"mt_43"},{"name":"PD-L1","id":"mt_25"}],"nctNumber":"NCT06868277","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2026-01-30T10:22:34+01:00","shortTitle":"ARTEMIDE-Lung04","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]},{"active":true,"description":"NIS zur Verträglichkeit Sicherheit und Wirksamkeit von Asciminib bei neu diagnostizierten und vorbehandelten Patienten mit Philadelphie Chromosom positiver chronischer myeloischer Leukämie in der chronischen Phase","eudractNumber":null,"id":12073,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"},{"id":"leu","name":"Leukämien"},{"id":"leu3","name":"Chronische myeloische Leukämie (CML)"}],"mutations":[],"nctNumber":"NCT07549516","phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2026-06-30T10:01:01+02:00","shortTitle":"ASC2Adhere","therapeutical":false,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]},{"active":true,"description":"German prospektiv registry for patients with CML previously treated with >2 TKIs switched to another TKI (Asciminib or any ATP-competitive TKI)","eudractNumber":null,"id":10655,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"},{"id":"leu","name":"Leukämien"},{"id":"leu3","name":"Chronische myeloische Leukämie (CML)"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_12","name":"N/A"},"recruitmentStart":"2024-04-30T15:42:04+02:00","shortTitle":"ASCANY","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Non-Interventional Study to Describe Real-World Treatment Patterns and Clinical \nOutcomes in Treatment-Naïve Chronic Lymphocytic Leukemia Patients Treated \nwith Fixed-Duration Acalabrutinib + Venetoclax ± Obinutuzumab as First-Line \nTherapy.","eudractNumber":null,"id":12322,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2026-04-15T10:23:31+02:00","shortTitle":"AVANTGARDE","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Multicenter, Open-label, Phase 1 Study of Allo-RevCAR01-T-CD123 Consisting of Genetically Modified T cells Carrying Reverse Chimeric Antigen Receptors (Allo-RevCAR01-T) in Combination With CD123 Target Module (R-TM123) for the Treatment of Patients With Selected Hematologic Malignancies Positive for CD123","eudractNumber":"2022-501797-19","id":8333,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"},{"id":"leu","name":"Leukämien"},{"id":"leu2","name":"Akute myeloische Leukämie (AML)"}],"mutations":[{"name":"CD (Cluster of Differentiation)","id":"mt_211"},{"name":"CD123 ","id":"mt_79"}],"nctNumber":"NCT05949125","phase":{"id":"ph_3","name":"Phase I"},"recruitmentStart":"2024-02-20T11:15:07+01:00","shortTitle":"AVC-201-01","therapeutical":true,"therapyLines":[{"id":"tl_2","name":"Zweitlinie"}]},{"active":true,"description":"Real World Evalauation of efficacy and safety with Avelumab+Axitinib in patients with advanced Renal-Cell Carcinoma (RCC) in multiple EU countries","eudractNumber":null,"id":7080,"indications":[{"id":"uro","name":"Urogenitale Tumoren (Niere, ableitende Harnwege, Hoden)"},{"id":"uro1","name":"Nierenzellkarzinom"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[{"name":"PD-1 (Programmed cell death protein 1)","id":"mt_43"},{"name":"PD-L1","id":"mt_25"}],"nctNumber":"NCT04941768","phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2021-07-22T08:18:43+02:00","shortTitle":"AVION","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Prospektive, multizentrische Registerstudie zur Bewertung verschiedener leitlinienkonformer Operationsverfahren in der Axilla (Sentinel-Node Biopsie, Targeted Axillary Dissection, Axilladissektion) nach neoadjuvanter Chemotherapie","eudractNumber":null,"id":7644,"indications":[{"id":"bru","name":"Brustkrebs (Mammakarzinom)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT04373655","phase":{"id":"ph_13","name":"Therapieoptimierung"},"recruitmentStart":"2020-06-04T13:27:58+02:00","shortTitle":"AXSANA / EUBREAST 3 – Studie","therapeutical":true,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"A\nPhase 3 Randomized Study To Evaluate The Safety and Efficacy Of ABBV-706 Versus SoC In Relapsed/Refractory\nExtensive Stage-Small Cell Lung Cancer, which provides high level information\non the study design and required subject population","eudractNumber":"2025-523819-11-00","id":11760,"indications":[{"id":"lun","name":"Lungentumoren"},{"id":"lun1","name":"Kleinzelliges Bronchialkarzinom (SCLC)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT07365241","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2026-09-17T14:20:26+02:00","shortTitle":"AbbVie M23-384","therapeutical":true,"therapyLines":[{"id":"tl_2","name":"Zweitlinie"},{"id":"tl_3","name":"Drittlinie"}]},{"active":true,"description":"An Open-label Multi-Cohort Phase 1b/2 Study to Evaluate the Safety, Efficacy, and Optimal Dose of ABBV-400 in Combination with Budigalimab in Advanced or Metastatic Non-Squamous NSCLC with No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations (AndroMETa-Lung-536)","eudractNumber":"2024-514465-18","id":10833,"indications":[{"id":"lun","name":"Lungentumoren"},{"id":"lun2","name":"Nicht-kleinzelliges Bronchialkarzinom (NSCLC)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT06772623","phase":{"id":"ph_15","name":"Phase IB/II"},"recruitmentStart":"2026-05-06T09:03:47+02:00","shortTitle":"AbbVie M24-536 [AndroMETa-Lung-536]","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"},{"id":"tl_2","name":"Zweitlinie"}]}]}